BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS

1 . A compound having the formula:

or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein

Y is —N— or —C(R 7 )—;

Z is —N— or —C(R 6 )—, such that at least one of Y and Z is other than —N—;

R 1 is —H, alkyl, —OH, —OR 9 , —SR 9 , or —N(R 10 ) 2 , wherein an alkyl group can be optionally substituted with one or more groups, which are each independently selected from halo, aryl, —OH, —O-haloalkyl, —O-alkyl, —CN, —N(R 10 ) 2 , —C(O)R 9 , —C(O)OR 9 , —C(O)N(R 10 ) 2 and —NHC(O)R 9 ;

R 2 is H, alkyl, alkenyl, —O-alkylene-O-alkyl, -(alkylene) n -aryl, -(alkylene) n -cycloalkyl, -(alkylene) n -heterocycloalkyl or -(alkylene) n -heteroaryl, wherein an alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl group can be optionally substituted with one or more groups, which are each independently selected from alkyl, haloalkyl, hydroxyalkyl, aryl, halo, —OH, —O-haloalkyl, —O-alkyl, —O-aryl, —O-alkylene-cycloalkyl, -alkylene-O-alkyl, —S(O) p R 13 , —CN, —N(R 10 ) 2 , —C(O)R 9 , —C(O)OR 9 , —C(O)N(R 10 ) 2 , —NHC(O)R 9 , —NHS(O) q R 13 and —S(O) q N(R 10 ) 2 ; or R 2 and R 3 and the carbon atom to which they are both attached combine to form a cycloalkyl or heterocycloalkyl group, either of which can be optionally substituted with one or more groups, which are each independently selected from alkyl, haloalkyl, hydroxyalkyl, halo, —OH, —O-haloalkyl, —O-alkyl, —O-aryl, -alkylene-O-alkyl, —CN, —N(R 10 ) 2 , —C(O)R 9 , —C(O)OR 9 , —C(O)N(R 10 ) 2 , —NHC(O)R 9 , —NHS(O) q R 13 , —S(O) p R 13 and —S(O) q N(R 10 ) 2 ; or R 2 and R 3 and the carbon atom to which they are both attached, combine to form a cycloalkyl or heterocycloalkyl group, wherein the cycloalkyl or heterocycloalkyl group can be optionally fused to one or two benzene rings;

R 3 is alkyl, alkenyl, -(alkylene) n -aryl, -(alkylene) n -cycloalkyl, -(alkylene) n -heterocycloalkyl, -(alkylene) n -heteroaryl or —P(O)(OCH 3 ) 2 , wherein an alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl group can be optionally substituted with one or more groups, which are each independently selected from alkyl, haloalkyl, hydroxyalkyl, aryl, halo, —OH, —O-haloalkyl, —O-alkyl, —O-aryl, —O-alkylene-cycloalkyl, -alkylene-O-alkyl, —S(O) p R 13 , —CN, —N(R 10 ) 2 , —C(O)R 9 , —C(O)OR 9 , —C(O)N(R 10 ) 2 , —NHC(O)R 9 , —NHS(O) q R 13 and —S(O) q N(R 10 ) 2 ;

R 4 , R 5 , R 6 and R 7 are each independently selected from H, -(alkylene) n —N(R 8 ) 2 , —S(O) p R 13 , —OR 12 , —C(O)OR 11 , —C(O)R 11 , alkyl, halo, haloalkyl, —CN, cycloalkyl, heteroaryl, heterocycloalkyl, —C(O)N(R 8 ) 2 , —C(═NOH)—NH 2 and -(alkylene) n -aryl, wherein any aryl, heteroaryl or heterocycloalkyl group can be optionally substituted with one or more groups, which are each independently selected from halo, alkyl, aryl, hydroxyalkyl, —O-alkyl, haloalkyl, —C(O)O-alkyl, —C(O)-alkyl, —NHC(O)O-alkyl, —C(O)NH-alkyl, —CN, —NO 2 , —S(O) 2 -alkyl and —S-alkyl, such that R 4 , R 5 , R 6 and R 7 are not each H, and wherein a heterocycloalkyl or heteroaryl group can be optionally fused to a benzene ring;

each occurrence of R 8 is independently H, alkyl, -alkylene-C(O)OR 11 , -(alkylene) n -aryl, -(alkylene) n -cycloalkyl, -(alkylene) n -heterocycloalkyl, -(alkylene) n -heteroaryl, -alkylene-O-alkyl, cyanoalkyl, alkenyl, alkynyl, haloalkyl or haloalkenyl, wherein an aryl, cycloalkyl, heterocycloalkyl or heteroaryl group can be optionally substituted with one or more groups, which are each independently selected from halo, alkyl, hydroxyalkyl, —OR 10 , haloalkyl, —CN, —NO 2 , —O-haloalkyl, —S-alkyl, —S-haloalkyl, -alkylene-O-alkyl, —CN, —N(R 12 ) 2 , —C(O)R 12 , —C(O)OR 12 , —C(O)N(R 12 ) 2 , —NHC(O)R 12 , —NHS(O) q R 14 , —S(O) p R 14 and —S(O) q N(R 12 ) 2 ;

each occurrence of R 9 is alkyl, alkenyl, alkynyl, haloalkyl, -alkylene-O-aryl, -alkylene-S-aryl, -alkylene-N(R 8 )C(O)O-alkyl, -(alkylene) n -aryl, -(alkylene) n -cycloalkyl, -(alkylene) n -cycloalkenyl, -(alkylene) n -heterocycloalkyl or -(alkylene) n -heteroaryl, wherein an aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heteroaryl group can be optionally substituted with one or more groups, which are each independently selected from halo, alkyl, hydroxyalkyl, —OR 10 , haloalkyl, —CN, —NO 2 , —O-haloalkyl, —S-haloalkyl, -alkylene-O-alkyl, —CN, —N(R 12 ) 2 , —C(O)R 12 , —C(O)OR 12 , —C(O)N(R 12 ) 2 , —NHC(O)R 12 , —NHS(O) q R 14 , —S(O) p R 14 and —S(O) q N(R 12 ) 2 ;

each occurrence of R 10 is independently H, alkyl, -(alkylene) n -aryl, -(alkylene) n -cycloalkyl, -(alkylene) n -cycloalkenyl, -(alkylene) n -heterocycloalkyl or -(alkylene) n -heteroaryl, wherein any of the above groups, excluding H, can be optionally substituted with one or more groups, which are each independently selected from alkyl, haloalkyl, hydroxyalkyl, halo, —OH, —O-haloalkyl, —O-alkyl, —O-aryl, -alkylene-O-alkyl, —CN, —N(R 12 ) 2 , —C(O)H, —C(O)R 12 , —C(O)OR 12 , —C(O)N(R 12 ) 2 , —NHC(O)R 12 , —NHS(O) q R 14 , —S(O) p R 14 and —S(O) q N(R 12 ) 2 ;

each occurrence of R 11 is independently H, alkyl, aryl, heterocycloalkyl, heteroaryl or cycloalkyl, wherein any of the above groups can be optionally substituted with one or more groups, which are each independently selected from alkyl, haloalkyl, hydroxyalkyl, halo, —OH, —O-haloalkyl, —O-alkyl, —O-aryl, -alkylene-O-alkyl, —CN, —N(R 12 ) 2 , —C(O)H, —C(O)R 12 , —C(O)OR 12 , —C(O)N(R 12 ) 2 , —NHC(O)R 12 , —NHS(O) q R 14 , —S(O) p R 14 and —S(O) q N(R 12 ) 2 ;

each occurrence of R 12 is independently H, alkyl, -(alkylene) n -aryl, heterocycloalkyl, heteroaryl or cycloalkyl;

each occurrence of R 13 is independently alkyl, aryl, heterocycloalkyl, heteroaryl or cycloalkyl, wherein any of the above groups can be optionally substituted with one or more groups, which are each independently selected from alkyl, haloalkyl, hydroxyalkyl, halo, —OH, —O-haloalkyl, —O-alkyl, —O-aryl, -alkylene-O-alkyl, —CN, —N(R 12 ) 2 , —C(O)H, —C(O)R 12 , —C(O)OR 12 , —C(O)N(R 12 ) 2 , —NHC(O)R 12 , —NHS(O) q R 14 , —S(O) p R 14 and —S(O) q N(R 12 ) 2 ;

each occurrence of R 14 is independently alkyl, -(alkylene) n -aryl, heterocycloalkyl, heteroaryl or cycloalkyl;

each occurrence of n is independently 0 or 1;

each occurrence of p is independently 0, 1 or 2; and

each occurrence of q is independently 1 or 2.

2 . The compound of claim 1 , wherein Y is —C(R 7 )— and Z is —C(R 6 )—.

3 . The compound of claim 1 , wherein Y is —N— and Z is —C(R 6 )—.

4 . The compound of claim 1 , wherein R 1 is alkyl, —OH or —NH 2 .

5 . (canceled)

6 . The compound of claim 1 , wherein R 2 and R 3 are each independently selected from haloalkyl, -(alkylene) n -aryl, -(alkylene) n -heteroaryl, -(alkylene) n -cycloalkyl and -alkylene-O-alkyl.

7 . The compound of claim 1 , wherein the group —CH(R 2 )(R 3 ) is:

8 . The compound of claim 1 , wherein at least one of R 2 and R 3 is phenyl.

9 . The compound of claim 8 , wherein R 2 and R 3 are each phenyl.

10 . (canceled)

11 . The compound of claim 1 , wherein R 5 is —N(R 8 ) 2 .

12 . The compound of claim 11 , wherein R 5 is —NHC(O)OR 11 , —NH-phenyl, or —N(alkyl)(phenyl), wherein the phenyl moiety of an —NH-phenyl or —N(alkyl)(phenyl) group can be unsubstituted or substituted as set forth in claim 1 .

13 . The compound of claim 4 , wherein R 2 and R 3 are each independently selected from haloalkyl, -(alkylene) n -aryl, -(alkylene) n -heteroaryl, -(alkylene) n -cycloalkyl and -alkylene-O-alkyl.

14 . The compound of claim 13 , wherein R 1 is methyl and R 2 and R 3 are each independently selected from phenyl, benzyl, pyridyl, -cycloalkyl and —CH 2 -O-alkyl.

15 . The compound of claim 14 , wherein at least one of R 2 and R 3 is phenyl.

16 . The compound of claim 15 , wherein R 2 and R 3 are each phenyl.

17 . (canceled)

18 . The compound of claim 2 , wherein R 6 is —N(R 8 ) 2 ,

19 - 21 . (canceled)

22 . A compound having the structure

or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.

23 . A composition comprising one or more compounds of claim 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, and at least one pharmaceutically acceptable carrier.

24 . A method for treating diabetes, a diabetic complication, obesity, metabolic syndrome or a cardiovascular disease in a patient, the method comprising administering to the patient an effective amount of one or more compounds of claim 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.

25 - 32 . (canceled)

33 . The compound of claim 1 having the formula selected from the group consisting of:

or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.